09:48 AM EST - Intellipharmaceutics International Inc. : Announced revenue related to the Company’s license and commercialization agreement with Par Pharmaceutical, Inc. was $0.6 million for the three months ended February 29, 2016 versus $1.1 million for the three months ended February 28, 2015. The Company recorded net loss for the three months ended February 29, 2016 of $2.1 million or $0.09 per diluted common share, compared with a net loss of $0.9 million or $0.04 per common share for the three months ended February 28, 2015. All amounts in U.S. dollars. Intellipharmaceutics International Inc.
shares T.I are trading unchanged at $2.75.
